Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors

Area of Science:

• Cancer immunotherapy
• Immunology
• Drug development

Background:

• Immune adjuvants are crucial in cancer biotherapy for stimulating anti-tumor immune responses.
• Clinical application of adjuvants is hindered by stability and efficacy challenges.
• Tuftsin, a known immunomodulator, serves as a basis for developing novel therapeutic agents.

Purpose of the Study:

• To synthesize and evaluate the antitumor activity of a novel tuftsin derivative, T peptide (TP), in preclinical cancer models.
• To investigate TP's efficacy specifically in postoperative residual tumor settings.
• To elucidate the immunomodulatory mechanisms underlying TP's anti-cancer effects.

Main Methods:

• Synthesis of a novel tuftsin derivative, TP, by linking four tuftsin peptides.
• Evaluation of TP's anticancer activity in postoperative residual tumor mouse models.
• In vitro assessment of TP's effects on macrophage function and tumor cell growth.
• Analysis of macrophage polarization (M1/M2) and production of cytotoxic factors (TNF-α, NO).

Main Results:

• TP demonstrated enhanced stability in vivo compared to native tuftsin.
• TP significantly inhibited residual tumor growth in postsurgical mice and human xenograft models.
• TP synergized macrophage functions, promoting a shift towards the anti-tumor M1 phenotype.
• TP treatment led to elevated cytotoxic TNF-α and NO production by macrophages.
• TP effectively prolonged survival in tumor-resected mice with minimal observed toxicity.

Conclusions:

• The novel T peptide (TP) exhibits potent antitumor activity, particularly in postoperative residual cancer settings.
• TP functions as an immunomodulator, enhancing macrophage-mediated anti-tumor immunity.
• TP holds significant potential as a postoperative adjuvant therapy to improve cancer treatment outcomes.